HSR Act Waiting Period Expires for Eli Lilly Acquisition

summarizeSummary

Centessa Pharmaceuticals announced that a key regulatory hurdle for its acquisition by Eli Lilly has been cleared, bringing the deal closer to closing.

check_boxKey Events

• HSR Act Waiting Period Expires

  The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired on May 21, 2026, satisfying a critical regulatory condition for the acquisition by Eli Lilly and Company.

• Acquisition Progresses

  This development moves the previously announced acquisition by Eli Lilly, valued at $38.00 per share plus a CVR, closer to completion.

• Remaining Conditions

  The acquisition is still subject to other customary closing conditions, including Centessa shareholder approval and sanction by the High Court of Justice of England and Wales.

auto_awesomeAnalysis

This 8-K announces the expiration of the Hart-Scott-Rodino (HSR) Act waiting period, a key regulatory condition for Eli Lilly's acquisition of Centessa Pharmaceuticals. This development is a positive step, reducing regulatory risk and moving the previously announced $38.00 per share cash-plus-CVR deal closer to completion. The stock is currently trading near its 52-week high, reflecting market confidence in the deal closing. The acquisition remains subject to shareholder approval and sanction by the UK High Court.